• Home
  • Search Results
  • The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors.

The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors.

Molecular and cellular biology (2009-08-26)
Mark Watson, Anne Roulston, Laurent Bélec, Xavier Billot, Richard Marcellus, Dominique Bédard, Cynthia Bernier, Stéphane Branchaud, Helen Chan, Kenza Dairi, Karine Gilbert, Daniel Goulet, Michel-Olivier Gratton, Henady Isakau, Anne Jang, Abdelkrim Khadir, Elizabeth Koch, Manon Lavoie, Michael Lawless, Mai Nguyen, Denis Paquette, Emilie Turcotte, Alvin Berger, Matthew Mitchell, Gordon C Shore, Pierre Beauparlant
ABSTRACT

GMX1777 is a prodrug of the small molecule GMX1778, currently in phase I clinical trials for the treatment of cancer. We describe findings indicating that GMX1778 is a potent and specific inhibitor of the NAD(+) biosynthesis enzyme nicotinamide phosphoribosyltransferase (NAMPT). Cancer cells have a very high rate of NAD(+) turnover, which makes NAD(+) modulation an attractive target for anticancer therapy. Selective inhibition by GMX1778 of NAMPT blocks the production of NAD(+) and results in tumor cell death. Furthermore, GMX1778 is phosphoribosylated by NAMPT, which increases its cellular retention. The cytotoxicity of GMX1778 can be bypassed with exogenous nicotinic acid (NA), which permits NAD(+) repletion via NA phosphoribosyltransferase 1 (NAPRT1). The cytotoxicity of GMX1778 in cells with NAPRT1 deficiency, however, cannot be rescued by NA. Analyses of NAPRT1 mRNA and protein levels in cell lines and primary tumor tissue indicate that high frequencies of glioblastomas, neuroblastomas, and sarcomas are deficient in NAPRT1 and not susceptible to rescue with NA. As a result, the therapeutic index of GMX1777 can be widended in the treatment animals bearing NAPRT1-deficient tumors by coadministration with NA. This provides the rationale for a novel therapeutic approach for the use of GMX1777 in the treatment of human cancers.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Hydrogen peroxide solution, 30 % (w/w) in H2O, contains stabilizer
Sigma-Aldrich
Hydrogen peroxide solution, contains inhibitor, 30 wt. % in H2O, ACS reagent
Sigma-Aldrich
Hydrogen peroxide solution, 50 wt. % in H2O, stabilized
Millipore
Hydrogen peroxide solution, 3%, suitable for microbiology
Sigma-Aldrich
Sodium L-lactate, ~98%
Supelco
Hydrogen peroxide solution, ≥30%, for trace analysis
Sigma-Aldrich
Sodium L-lactate, ≥99.0% (NT)
Sigma-Aldrich
Hydrogen peroxide solution, contains ~200 ppm acetanilide as stabilizer, 3 wt. % in H2O
Supelco
Hydrogen peroxide solution, 30 % (w/w), for ultratrace analysis
Sigma-Aldrich
Hydrogen peroxide solution, 34.5-36.5%
Sigma-Aldrich
Diaphorase from Clostridium kluyveri, lyophilized powder, 3.0-20.0 units/mg protein (biuret)
Sigma-Aldrich
Hydrogen peroxide solution, contains inhibitor, 30 wt. % in H2O, meets USP testing specifications
Supelco
Sodium L-lactate, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Hydrogen peroxide solution, contains inhibitor, 35 wt. % in H2O
Sigma-Aldrich
Hydrogen peroxide solution, tested according to Ph. Eur.
Sigma-Aldrich
Hydrogen peroxide solution, purum p.a., ≥35% (RT)
Sigma-Aldrich
Diaphorase from Clostridium kluyveri, recombinant, expressed in E. coli, Animal-component free
Sigma-Aldrich
Hydrogen peroxide solution, contains potassium stannate as inhibitor, 30-32 wt. % in water, semiconductor grade, 99.999% trace metals basis
Sigma-Aldrich
GMX1778, ≥98% (HPLC)